Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesFDA approves Exforge HCT - the only high blood pressure treatment to combine three medications in a single pill
Novartis, 05/01/09
The US Food and Drug Administration (FDA) has approved Exforge HCT, the only single pill to combine the three most prescribed high blood pressure treatments in their classes in the US[3]: the calcium channel blocker amlodipine, the angiotensin receptor blocker valsartan, and the diuretic hydrochlorothiazide. Exforge HCT is an important new option for patients who have tried taking dual combinations of these classes of blood pressure medications without success.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
Malaria Journal, 12/01/09
Pharmacokinetic—pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide
Clinical Therapeutics, 12/01/09
Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
Annals of Pharmacotherapy, 11/25/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Allos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
Allos Therapeutics, 12/01/09
Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09
Medtronic Receives FDA Warning Letter Following Inspection of Its Mounds View, Minn. Facility
Medtronic, 11/19/09
Sponsor
Article Search
Sponsor